Cargando…

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

Pamiparib, an investigational Poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development, demonstrates excellent selectivity for both PARP1 and PARP2, and superb anti-proliferation activities in tumor cell lines with BRCA1/2 mutations or HR pathway deficiency (HRD). Pamiparib has good bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Yao, Guo, Yin, Liu, Ye, Wang, Hexiang, Gong, Wenfeng, Liu, Yong, Wang, Xing, Gao, Yajuan, Yu, Fenglong, Su, Dan, Wang, Fan, Zhu, Yutong, Zhao, Yuan, Wu, Yiyuan, Qin, Zhen, Sun, Xuebing, Ren, Bo, Jiang, Bin, Jin, Wei, Shen, Zhirong, Tang, Zhiyu, Song, Xiaomin, Wang, Lai, Liu, Xuesong, Zhou, Changyou, Jiang, Beibei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350150/ https://www.ncbi.nlm.nih.gov/pubmed/32652442 http://dx.doi.org/10.1016/j.neo.2020.06.009

Ejemplares similares

Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report
por: Huang, Xiaoyan, et al.
Publicado: (2022)

Human Mass Balance and Metabolite Profiling of [(14)C]‐Pamiparib, a Poly (ADP‐Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer
por: Mu, Song, et al.
Publicado: (2021)

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
por: Xu, Binghe, et al.
Publicado: (2022)

Pamiparib dose escalation in Chinese patients with non‐mucinous high‐grade ovarian cancer or advanced triple‐negative breast cancer
por: Xu, Binghe, et al.
Publicado: (2020)

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
por: Chen, Xin, et al.
Publicado: (2022)

Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
por: Wu, Xiaohua, et al.
Publicado: (2022)

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial
por: Friedlander, Michael, et al.
Publicado: (2023)

Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
por: Divan, Ali, et al.
Publicado: (2020)

Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results
por: Ciardiello, Fortunato, et al.
Publicado: (2023)

Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
por: Nizi, Maria Giulia, et al.
Publicado: (2023)

Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution
por: He, Jin-Xue, et al.
Publicado: (2016)

The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy
por: Li, Zhenzhen, et al.
Publicado: (2021)

Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors
por: Yu, Jiang, et al.
Publicado: (2022)

Uncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
por: Wang, Shuai, et al.
Publicado: (2019)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

Isolation and Characterization of a Phaseolus vulgaris Trypsin Inhibitor with Antiproliferative Activity on Leukemia and Lymphoma Cells
por: Li, Miao, et al.
Publicado: (2017)

MET inhibition enhances PARP inhibitor efficacy in castration‐resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways
por: Zhou, Sihai, et al.
Publicado: (2021)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

In-plane Isotropic Microwave Performance of CoZr Trilayer in GHz Range
por: Pan, Lulu, et al.
Publicado: (2016)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Mycomedicine: A Unique Class of Natural Products with Potent Anti-tumour Bioactivities
por: Dai, Rongchen, et al.
Publicado: (2021)

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
por: Bian, X, et al.
Publicado: (2018)

PARP inhibitors in gastric cancer: beacon of hope
por: Wang, Yali, et al.
Publicado: (2021)

LCS-1 inhibition of superoxide dismutase 1 induces ROS-dependent death of glioma cells and degradates PARP and BRCA1
por: Ling, Min, et al.
Publicado: (2022)

PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia
por: Wang, Ling, et al.
Publicado: (2023)

Characterization and Evaluation of Resistance to Powdery Mildew of Wheat–Aegilops geniculata Roth 7M(g) (7A) Alien Disomic Substitution Line W16998
por: Wang, Yajuan, et al.
Publicado: (2020)

A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode
por: Zhao, Dongping, et al.
Publicado: (2022)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
por: Soni, Aashish, et al.
Publicado: (2022)

Large-scale transcriptome comparison reveals distinct gene activations in wheat responding to stripe rust and powdery mildew
por: Zhang, Hong, et al.
Publicado: (2014)

The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
por: Mu, Song, et al.
Publicado: (2021)

PARP inhibitor resistance: the underlying mechanisms and clinical implications
por: Li, He, et al.
Publicado: (2020)

Human Tyr-tRNA synthetase is a potent PARP-1 activating effector target for resveratrol
por: Sajish, Mathew, et al.
Publicado: (2014)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
por: Qin, Changjiang, et al.
Publicado: (2022)

Genome-wide identification and functional prediction of novel and fungi-responsive lincRNAs in Triticum aestivum
por: Zhang, Hong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q7q126gq88l10vqd1hospqluvt